Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDWAR:KRK +1.20%87 Days Payable is 57.05 as of Mar. 2026, which is 17% below its 10-year median of 68.97. GuruFocus rates WAR:KRK with a GF Score™ of 87/100 and a GF Value™ of zł649.77 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 926 Drug Manufacturers companies, Krka DD ranks worse than 66.95% on this metric.
Krka DD's average Accounts Payable for the
three
months ended in Mar. 2026 was zł614 Mil. Krka DD's Cost of Goods Sold for the
three
months ended in Mar. 2026 was zł981 Mil.
Hence, Krka DD's Days Payable for the
three
months ended in Mar. 2026 was 57.05.
The historical rank and industry rank for Krka DD's Days Payable or its related term are showing as below:
WAR:KRK'
s Days Payable Range Over the Past 10 Years
Min: 58.05 Med: 68.97 Max: 80.24
Current: 62.08
During the past 13 years, Krka DD's highest Days Payable was 80.24. The lowest was 58.05. And the median was 68.97.
WAR:KRK's Days Payable is ranked worse than 66.95% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.455
vs WAR:KRK: 62.08
Krka DD's Days Payable
declined
from Mar. 2025 (64.40) to Mar. 2026 (57.05).
It may suggest that Krka DDaccelerated paying its suppliers.
Krka DD Days Payable Related Terms
Krka DD Days Payable Historical Data
* Premium members only.
The historical data trend for Krka DD's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:KRK vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's Days Payable distribution charts can be found below:
* The bar in red indicates where Krka DD's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Krka DD's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (WAR:KRK) has a Days Payable of 57.05 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Krka DD and its competitors. This is 17% below median its historical median of 68.97. Over the past decade, Krka DD's Days Payable has ranged from 58.05 to 80.24. According to the industry distribution chart, Krka DD ranks #620 out of 926 companies in the Drug Manufacturers industry, placing it in the top 67%.
Is Krka DD's Days Payable too high?
Krka DD's current Days Payable of 57.05 is 17% below median its 10-year median of 68.97. Over the past 10 years, this metric has ranged from a low of 58.05 to a high of 80.24. The Drug Manufacturers industry median Days Payable is 90.46. Krka DD's value of 57.05 is 36.9% below this industry median. Based on the distribution chart, Krka DD ranks #620 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Krka DD has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #620 out of 926 companies for Days Payable. This places Krka DD in the lower half of its industry. The industry median Days Payable is 90.46. Krka DD's value of 57.05 is 36.9% below this benchmark. Historically, Krka DD's own Days Payable has ranged from 58.05 to 80.24 over the past decade. While the company's 10-year median is 68.97 vs. the industry median of 90.46, Krka DD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.46, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current Days Payable of 57.05 is 36.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current Days Payable is 57.05, which is 17% below median its own 10-year median of 68.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (WAR:KRK) is currently considered Significantly Overvalued. The stock's GF Value™ is zł649.77, compared to a current price of zł1,178.00 — trading 81.3% above its estimated fair value. The current Days Payable is 57.05, which is 17% below median its 10-year median of 68.97 and 36.9% below the Drug Manufacturers industry median of 90.46. Krka DD's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Krka DD (WAR:KRK), the current Days Payable is 57.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (WAR:KRK) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of zł1,178.00 is trading 81.3% above its estimated GF Value™ of zł649.77.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for WAR:KRK:
Days Payable: 57.05 (17% below median its 10-year median of 68.97)
GF Value™: zł649.77 vs. price of zł1,178.00 (81.3% above fair value)
Industry Position: 36.9% below the Drug Manufacturers median (#620 of 926)
No single metric tells the full story. See the WAR:KRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
87GF Score
Get the complete analysis for WAR:KRK
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:KRK has been successfully added to your 
